Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 

Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Award

Photo Pending

George Jackson, M.D., Ph.D.

University of Texas Medical Branch
Galveston, TX

Title: Validation and Characterization of Tau Modifiers In Vivo
Non-Technical Title: Examining regulation of tau protein

Acknowledgements: In memory of Marion Ahlstrom Hoffman
Duration: April 1, 2007 - August 31, 2010
Award Type: Standard
Award Amount: $400,000


Summary:

These experiments propose further studies of the role of PSA in tauopathy, and plan to validate other genes identified as putative protective or susceptibility genes in the transgenic human tau P301L mouse model.

Details:


Neurofibrillary tangles containing tau are a hallmark of Alzheimer’s disease. However, little is known about ways to protect brain cells from degeneration caused by tau. We looked at gene expression in several parts of the brain of mice expressing human tau including a mutation that causes FTD. This was done in combination with testing in the simple fruit fly. We identified several novel modifiers of tau neurotoxicity including the highly conserved protein, puromycin-sensitive aminopeptidase (PSA). Here, we propose further studies of the role of PSA in tauopathy, and plan to validate other genes identified as putative protective or susceptibility genes in the transgenic human tau P301L mouse model. These will involve crossing fruit flies that express tau with other lines that have greater and/or lesser expression of the genes identified in the mouse. Genes that succeed in changing tau toxicity can easily be identified under the microscope by examining the size of the fly eye. Validation and characterization of mechanisms of action of tau modifiers using the fly model will provide a first step toward identifying those modifiers which are most promising as therapeutic targets for AD; these may then be further studied in cell culture and mice.

Publications:

Ratnaparkhi A, Lawless GM, Schweizer FE, Golshani P, Jackson GR (2008) A Drosophila Model of ALS: Human ALS-Associated Mutation in VAP33A Suggests a Dominant Negative Mechanism. PLoS ONE 3(6): e2334. PubMed Icon Google Scholar Icon